For the Inventor, By the Inventor

Enter assignee name

Berlin, Germany

Glycotope Gmbh

USPTO Granted Patents = 26

CIPO Patents = 26

EPO Patents = 25

Trademarks = 7

Forward Citations = 93

Loading Chart...

Loading Chart...

34 inventors (with patents filed for the assignee):

Steffen Goletz (22 out of 25 patents)

Antje Danielczyk (10 out of 15 patents)

Renate Stahn (6 out of 8 patents)

4. Uwe Karsten (6 out of 9 patents)

5. Lars Stöckl (5 out of 6 patents)

6. Hans Baumeister (5 out of 6 patents)

7. Philippe Ulsemer (3 out of 3 patents)

8. Anja Löffler (3 out of 3 patents)

9. Frederick Gyapon Quast (2 out of 3 patents)

10. Jan Susan Rosenbaum (2 out of 9 patents)

11. Matthias Kaup (2 out of 3 patents)

12. Lars Stoeckl (2 out of 2 patents)

13. Rik J Scheper (2 out of 2 patents)

14. Alan Masterson (2 out of 2 patents)

15. Herbert M Pinedo (2 out of 2 patents)

26 patents: Sort by Forward Citations

1. 12391956 - Methods, compositions and cells for preparing surfactant protein D (SP-D) (2025-08-19),

2. 12297289 - Anti-MUC1 antibody (2025-05-13),

3. 10752914 - Methods, compositions and cells for preparing surfactant protein D (SP-D) (2020-08-25),

4. 10280230 - Use of human cells of myeloid leukemia origin for expression of antibodies (2019-05-07),

5. 10184135 - Eukaryotic expression vectors comprising regulatory elements of the globin gene clusters (2019-01-22),

6. 9845361 - Recognition molecules for the treatment and detection of tumors (2017-12-19),

7. 9700610 - Microorganisms carrying a tumor antigen (2017-07-11),

8. 9527899 - Recombinant human follicle-stimulating hormone (2016-12-27),

9. 9494587 - Microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates (2016-11-15),

10. 9487567 - Method for the production of an immunostimulating mucin (MUC1) (2016-11-08),

11. 9359439 - Fab-glycosylated antibodies (2016-06-07),

12. 9359427 - Methods for culturing human myeloid leukaemia cells and cells derived therefrom (2016-06-07),

13. 9217038 - MUC1 antibodies (2015-12-22),

14. 9051370 - Humanized EGFR antibodies (2015-06-09),

15. 9051356 - Use of human cells of myeloid leukaemia origin for expression of antibodies (2015-06-09),

Glycotope GmbH is a biotechnology company specializing in the development and production of innovative glycobiology-based therapeutics. They utilize their expertise in glycoengineering to create highly specific and effective drugs for the treatment of cancer and other diseases. Through their advanced technologies, Glycotope aims to improve patient outcomes and contribute to the advancement of precision medicine.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

26 Patents

#39 in D-1000 Berlin

#1,812 in Germany

#24,051 in the World

Berlin, Germany

Glycotope Gmbh

Forward Citations = 93

34 inventors:

Steffen Goletz (22 out of 25 patents)

Antje Danielczyk (10 out of 15 patents)

Renate Stahn (6 out of 8 patents)

4. Uwe Karsten (6 out of 9 patents)

5. Lars Stöckl (5 out of 6 patents)

Please report any incorrect information to support@idiyas.com

Loading…